Grand Pharmaceutical Group Limited (0512) Price & Analysis

Grand Pharmaceutical Group Limited, an investment holding entity, maintains a comprehensive involvement across the healthcare and related industries. Its core activities encompass the research, development, manufacturing, and commercialization of a diverse array of products, including pharmaceutical formulations, medical devices, biotechnology and wellness items, and essential pharmaceutical raw materials. The company's extensive pharmaceutical portfolio features critical cerebro-cardiovascular emergency medicines, alongside treatments for respiratory conditions, ophthalmic ailments, infections, ear-nose-throat (ENT) issues, various oncological diseases, and rare disorders. Within the medical devices sector, Grand Pharmaceutical offers advanced solutions such as vascular interventional devices. Prominent among these are paclitaxel-eluting coronary balloon dilatation catheters and paclitaxel-eluting hemodialysis shunt balloon dilatation catheters. Additionally, the company supplies a range of ophthalmology-specific devices. Its biotechnology and health product division provides offerings like Taurine, amino acid derivatives, steroid compounds, and environmentally conscious bio-pesticides, coupled with agricultural antibiotics. The firm also produces a wide spectrum of specialized pharmaceutical raw materials, encompassing substances such as metronidazole, chloramphenicol, epinephrine, dimethyl sulfate, and nitromethane. Beyond these primary areas, Grand Pharmaceutical's operations extend to agrochemicals, fine chemicals, and chemical medicines. They also develop ophthalmic gels and eye drops, supply active pharmaceutical ingredients (APIs) for steroid hormones and their intermediates, and produce bio-pesticides and additives. The company further delves into disposable surgical products, traditional Chinese medicine, and health food items, even engaging in sewage treatment. A strategic collaboration is in place with the Eye Hospital of Wenzhou Medical University, specifically aimed at advancing ophthalmic drug research and development. Grand Pharmaceutical Group boasts a significant international footprint, conducting business in the People's Republic of China, other parts of Asia, the United States, Europe, and various global markets. Established in 1995 and headquartered in Central, Hong Kong, the company adopted its present name in November 2021, having previously been known as China Grand Pharmaceutical and Healthcare Holdings Limited.